Literature DB >> 9525833

The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up.

C M Dirven1, J Koudstaal, J J Mooij, W M Molenaar.   

Abstract

The proliferative potential of 39 pilocytic and 5 low grade astrocytomas was studied in relation to the Ki-67 activity as measured by the MIB-1 Labelings Index. The results were correlated to the biological behaviour of the tumor as measured by clinical and neuro-radiological (CT- or MRI-scans) follow-up of the patient. This study was undertaken to answer the question whether MIB-1 expression reflects differences in biological behaviour of these tumors, such as rapid progression of residual tumor or stable remaining tumor. MIB-1 LI values ranged from 0 to 19% in the group of pilocytic astrocytomas (mean 4.2%) and from 0 to 15% in the 5 low grade astrocytomas (mean 4,2%). All patients were operated and 23 of them had incomplete tumor resection as proven on postoperative neuro-imaging studies. Those 23 patients could be subdivided into two groups; one without progression of residual tumor during follow-up (n=12) and the other with tumor progression (n=11). mean MIB-1 LI in the group with 'quiescent' tumor tended to be lower than in the group with progressive tumor: 3,3% vs. 6,6%. Residual tumors which were negative for MIB-1 staining showed fewer progressions of residual tumor compared to those being positive for MIB-1 staining, however this difference was not significant (p=0, 15, Fisher exact test). Tumor samples of a second operation of the same patient had lower MIB-1 LI values than those of the samples taken at first operation. The proliferating potential seemed to be decreased after part of the tumor was resected. Pilocytic astrocytomas with a negative MIB-1 LI are unlikely to show progression of residual tumor after partial resection. MIB-1 staining might be an additional tool in determining the frequency and duration of follow-up and in making decisions regarding further treatment of a patient operated for a pilocytic astrocytoma with residual tumor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525833     DOI: 10.1023/a:1005905009449

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues.

Authors:  J Gerdes; M H Becker; G Key; G Cattoretti
Journal:  J Pathol       Date:  1992-09       Impact factor: 7.996

2.  Correlation between nucleolar organizer region staining and Ki-67 immunostaining in human gliomas.

Authors:  A Hara; H Hirayama; N Sakai; H Yamada; T Tanaka; H Mori
Journal:  Surg Neurol       Date:  1990-05

3.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.

Authors:  D N Louis; S Edgerton; A D Thor; E T Hedley-Whyte
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

5.  The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours.

Authors:  C B Ostertag; B Volk; T Shibata; P Burger; P Kleihues
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

Review 6.  Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature.

Authors:  C M Dirven; J J Mooij; W M Molenaar
Journal:  Childs Nerv Syst       Date:  1997-01       Impact factor: 1.475

7.  Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

Authors:  S W Coons; P C Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

8.  Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.

Authors:  S Ito; T Hoshino; M Shibuya; M D Prados; M S Edwards; R L Davis
Journal:  Neurosurgery       Date:  1992-09       Impact factor: 4.654

9.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

Authors:  P Zuber; M F Hamou; N de Tribolet
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

10.  Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.

Authors:  K Onda; R L Davis; M Shibuya; C B Wilson; T Hoshino
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

View more
  11 in total

Review 1.  Gamma Knife treatment of low-grade gliomas in children.

Authors:  Murat Şakir Ekşi; Baran Yılmaz; Akın Akakın; Zafer Orkun Toktaş; Ahmet Cemil Kaur; Mustafa Kemal Demir; Türker Kılıç
Journal:  Childs Nerv Syst       Date:  2015-07-15       Impact factor: 1.475

2.  Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression.

Authors:  S Khoshyomn; S Lew; J DeMattia; E B Singer; P L Penar
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Spontaneous regression of residual low-grade cerebellar pilocytic astrocytomas in children.

Authors:  Roxana S Gunny; Richard D Hayward; Kim P Phipps; Brian N Harding; Dawn E Saunders
Journal:  Pediatr Radiol       Date:  2005-07-27

Review 4.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

5.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 6.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 7.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

8.  Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.

Authors:  Fausto J Rodriguez; Caterina Giannini; Yan W Asmann; Mukesh K Sharma; Arie Perry; Kathleen M Tibbetts; Robert B Jenkins; Bernd W Scheithauer; Shrikant Anant; Sarah Jenkins; Charles G Eberhart; Jann N Sarkaria; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

9.  Activation of the Hedgehog pathway in pilocytic astrocytomas.

Authors:  Sarah Z Rush; Ty W Abel; Juan G Valadez; Matthew Pearson; Michael K Cooper
Journal:  Neuro Oncol       Date:  2010-03-11       Impact factor: 12.300

10.  Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival.

Authors:  Hidehiro Takei; Subashini T Yogeswaren; Kwong-Kwok Wong; Vidya Mehta; Murali Chintagumpala; Robert C Dauser; Ching C Lau; Adekunle M Adesina
Journal:  J Neurooncol       Date:  2007-08-10       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.